Incyte's Jakafi (ruxolitinib) Phase 1/2 Trial Progresses in Immune-Mediated Bone Marrow Failure
JAK1/2 Inhibitor Jakafi's New Challenges and Mechanism
Incyte's Jakafi (ruxolitinib) is a targeted therapy that selectively inhibits Janus kinase 1 and 2 (JAK1/JAK2). This Phase 1/2 study is evaluating Jakafi in patients with recurrent/refractory immune-mediated bone marrow failure, a condition where hematopoietic stem cells are destroyed due to immune system abnormalities. The drug works by blocking the intracellular JAK-STAT signaling pathway, thereby preventing abnormal T-cell attacks and reducing levels of inflammatory cytokines in the bone marrow microenvironment. This mechanism, which helps restore hematopoietic function, is expected to contribute to preventing bone marrow cell apoptosis and improving peripheral blood cell counts.
Limitations of Existing Standard Treatment and Unmet Medical Needs
Patients with severe aplastic anemia (SAA) are constantly exposed to the risk of severe anemia and infection. The current standard of care involves aggressive immunosuppressive therapy with antithymocyte globulin (hATG) and cyclosporine (CsA), but a significant number of patients do not respond to or relapse after this treatment. Eltrombopag (Promacta), from Novartis, is used as a second-line treatment, but there is still a large unmet need. Given that the global bone marrow failure market is estimated at $700 million to $6.9 billion, securing an effective oral targeted therapy for refractory patients is a key to changing the market landscape.
NIH-Led NHLBI-Sponsored Clinical Trial Design and Progress
This clinical trial (NCT05998408) is a single-center Phase 1/2 study sponsored by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). The trial began on February 20, 2024, and has already passed its primary completion date of July 22, 2025. It is currently in the active, not recruiting phase, with patients undergoing observation. Researchers are administering ruxolitinib orally to adult patients for six months and tracking efficacy through bone marrow biopsies and computed tomography (CT) scans. The final clinical trial completion date is set for June 3, 2032, and the accumulated data will be presented at future conferences.
Commercial Value and Value Creation Perspective
Jakafi generated revenues of $2.79 billion in 2024 and $3.09 billion in 2025, and is a key asset for Incyte, expanding beyond indications such as myelofibrosis. If Jakafi receives approval for this immune-mediated bone marrow failure indication, it can quickly gain market share due to its superior convenience compared to high-cost hematopoietic stem cell transplantation (HSCT) or inpatient treatments. From an investor's perspective, this is seen as a smart strategy for lifecycle management in preparation for patent expiration. By collaborating with the NHLBI, a public institution, Incyte can reduce development costs while securing clinical evidence, making this a commercially valuable move.
This Phase 1/2 trial offers a new JAK1/2 inhibitor-based treatment option for patients with recurrent/refractory immune-mediated bone marrow failure who do not respond to the current standard of care (SOC) of antithymocyte globulin (hATG) and cyclosporine (CsA) combination therapy, or to Eltrombopag, a second-line treatment from Novartis. In the global aplastic anemia market, estimated at $700 million to $6.9 billion annually, Jakafi has high commercial value as an oral targeted therapy that eliminates the need for inpatient treatment, and may lead to a shift in the treatment paradigm by reducing the proportion of high-cost hematopoietic stem cell transplantation (HSCT) in the future. In the short term, it will proactively secure efficacy data for Jakafi in the field of hematological diseases based on the Phase 1 data completed in July 2025, and in the medium to long term, it will serve as a product lifecycle extension strategy in response to patent expiration. Through the collaboration model with the NHLBI, a research institute of the NIH, Incyte will share clinical development risks and costs while proactively establishing clinical evidence with the potential to be first-in-class in the field of difficult-to-treat hematological diseases.
Source: ClinicalTrials.gov (api_ct)